MLManthana Laichapis

Manthana Laichapis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manthana Laichapis has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study

    by Manthana Laichapis, Rungpetch Sakulbumrungsil, Khunjira Udomaksorn, Nusaraporn Kessomboon, Osot Nerapusee, Charkkrit Hongthong, Sitanun Poonpolsub

    Background: Thailand’s pharmaceutical industry is prioritizing innovation and self-reliance through the development of incrementally modified drugs (IMDs), particularly sustained-release dosage forms. However, the financial feasibility of IMD development remains underexplored. Objective: This study evaluates the financial feasibility of developing sustained-release IMDs in Thailand, focusing on costs, timelines, and investment requirements to inform strategic decision-making. Methods: A mixed methods approach was used, combining literature reviews, expert interviews, and financial modeling. Two scenarios were analyzed: (1) only development (phase I) and (2) full clinical trials (phase I to III). Sensitivity analysis was used to assess the impact of key variables on financial feasibility. Results: The research and development (R&D) process for sustained-release IMDs takes 7 years for phase I–only development, costing US $1.46‐3.09 million, and 11 years for full clinical trials, costing US $18.60‐20.23 million. Process validation batches accounted for 60% of costs in phase I–only scenarios, while clinical trials represented 70% of costs in full clinical trial scenarios. The annual income required for a 5-year payback period ranged from US $0.20‐1.80 million (phase I only) to US $3.01‐27.11 million (full trials). Shorter R&D durations and longer payback periods substantially improved feasibility. Conclusions: Developing sustained-release IMDs in Thailand involves substantial costs and extended timelines but offers a lower-risk alternative to new chemical entities. Strategic investments, efficient R&D processes, and supportive policies are essential to enhance feasibility and alignment with national goals of innovation and self-reliance.


  • Open Access

    Authors’ Response to Peer Reviews of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”

    by Manthana Laichapis, Rungpetch Sakulbumrungsil, Khunjira Udomaksorn, Nusaraporn Kessomboon, Osot Nerapusee, Charkkrit Hongthong, Sitanun Poonpolsub

    This is the author(s)’ responses to peer review reports related to MS ID#65978